A retrospective cohort study found that lipids and albumin had only a little impact on the apparent mycophenolic acid clearance in pediatric transplant recipients.

• Mark-Christoph Müller

  English

  Author

• Florian Reitz

  English

  Author

• Nicolas Roy

  English

  Author

Therapeutic drug monitoring (TDM) is necessary for critical dosage medications, such as calcineurin inhibitors and inhibitors
of the mammalian target of rapamycin (MTOR), in the context of juvenile kidney transplantation [1]. Mycophenolate
mofetil's (MMF) TDM has been required since discussed [2]. There is mounting evidence that TDM of mycophenolic acid
(MPA), the active ingredient of MMF, may assist prevent underexposure and enable maintenance of the target exposure area-
under-the-time concentration curve (AUC) of 30–60 mg*h/L, which may lessen rejection in the early post-renal transplant
period [3-5]. The benefits of long-term MPA monitoring following transplantation are less well-established, despite When
considering a fixed combination of tacrolimus and MMF, the trough level might be a viable biomarker of exposure [6]. Long-
term MPA underexposure may be linked to the development of de novo donor-specific antibodies (DSA) [7, 9], which are
linked to poorer graft outcomes [10, 11], according to some recent data.

• pdf